Recently, researchers found that novel adipokine Gremlin 1 can antagonize insulin signaling, is positively correlated with the percentage of body fat and IR in T2DM and NAFLD/NASH subjects, and also could represent a potential biomarker or therapeutic target [95]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.